CA-ANDERSEN-GLOBAL
29.9.2023 17:25:34 CEST | Business Wire | Pressemeddelelse
Andersen, det hurtigst voksende uafhængige, tværfaglige professionelle servicefirma i verden, har lanceret en ny global værdiansættelsespraksis. Ønsket er at udvide kundeplatformen med skattemæssige, juridiske og beslægtede services. Andersens globale værdiansættelsesteam arbejder med virksomheder, fonde, enkeltpersoner med stor indre værdi og familiekontorer om udførelse af værdiansættelser af virksomheder, materielle og immaterielle aktiver og komplekse værdipapirer med henblik på indberetning af skat, rapportering af finansielle oplysninger og rådgivning i transaktionsspørgsmål. Kundegrundlaget er en bred vifte af brancher inden for alt fra teknologi til fremstilling og fra landbrug til biomedicin.
På lanceringstidspunktet eksisterer Andersens globale værdiansættelsespraksis i mere end 20 lande verden over på tværs af Nordamerika, Europa, Latinamerika, Mellemøsten og Asien.
"Skat, jura og værdiansættelse er tæt forbundne, men ingen anden professionel servicevirksomhed tilbyder alle disse faciliteter på globalt plan under samme tag," udtaler Andersen Global Chairman og CEO Mark Vorsatz. "Hos Andersen har vi en vision om at skabe en platform, hvor kunderne får en problemfri oplevelse af én tværfaglig virksomhed, de kan stole på, hvor som helst i verden. Vores mål er at blive et af de største uafhængige værdiansættelsesfirmaer i verden inden for de næste få år."
I spidsen for Andersens nye globale værdiansættelsespraksis står Managing Director Sid Luckenbach, som på nationalt plan i USA har stået for firmaets udbud af værdiansættelse i de seneste 18 år.
"Forretningsstrukturer og finansielle instrumenter bliver mere komplekse," siger Luckenbach. "Kompleksiteten stiger, når man har at gøre med grænseoverskridende transaktioner på tværs af flere retsområder. Derfor er den traditionelle tilgang ikke længere tilstrækkelig. Vores globale værdiansættelsespraksis samler den bundsolide ekspertise og geografiske rækkevidde, som kunderne efterspørger, uanset hvor deres aktiver er placeret."
Andersen Global er en international sammenslutning af juridisk adskilte og uafhængige medlemsvirksomheder, der består af skatteeksperter og -jurister i hele verden. Andersen Global, der blev etableret i 2013 af den amerikanske medlemsvirksomhed Andersen Tax LLC, har nu mere end 14.000 eksperter i hele verden og en tilstedeværelse på over 400 lokaliteter gennem sine medlemsvirksomheder og samarbejdsvirksomheder.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20230927729165/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
